TrialJournal of neuro-oncology2019

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).

John D Hainsworth et al.PubMed ↗Publisher ↗

No numbers read from the abstract.